Strengthening these findings, more recently, the activation of mTOR was able to enrich the pool of CSCs within DCCs in bone marrow (BM) metastatic niches in prostate cancer models, through a mechanism involving the release of growth arrest specific 6 (GAS6) by osteoblasts (103). Here, GAS6 is linked to prostate cancer.